Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
About this trial
This is an interventional prevention trial for Post-ERCP Acute Pancreatitis
Eligibility Criteria
Inclusion Criteria: Suspected sphincter of Oddi dysfunction History of post ERCP Pancreatitis Pancreatic instrumentation or sphincterotomy. Precut sphincteroyomy Difficult cannulation defined by more than 5 cannulation attempts The use of double wire technique in bile duct access At least 2 of the followings including Female age < 50 year 3 pancreatogram Acinarization (Contrast injection to tail of pancreas Normal serum bilirubin Guidewire to the tail of pancreas or secondary branches Exclusion Criteria: Patient planned for pancreatic stenting Without informed consent Age < 18 years Pregnant women Lactating women Patient with altered anatomy Contraindications to the use of NSAIDS Renal failure Ongoing or recent hospitalisation for acute pancreatitis Allergy to aspirin or NSAIDs known chronic calcific pancreatitis -
Sites / Locations
- Department of Gastroenterology and Hepatology, MLN Medical college and SRN Hospital
- Department of Gastroenterology and HepatologyRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Rectal indomethacin
Pancreatic duct stent and rectal indomethacin